Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation Strategies in Pediatric AML
NCT06211452Phase 3Completed
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
- Start
- Aug 2007
- Primary completion
- Mar 2015
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
01
Overview
A Phase 3 trial of cytarabine, idarubicin, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML), sponsored by Grupo Argentino de Tratamiento de la Leucemia Aguda. Started Aug 2007; status: completed.
02
Drugs
cytarabineidarubicinmitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06211452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211452.